Clinical Trial Update: A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) [Phase 3]

View source ↗

Summary

Phase 3 trial investigating remestemcel-L (ex vivo cultured mesenchymal stromal cells) for pediatric steroid-refractory acute GVHD; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Remestemcel-L (mesenchymal stromal cells)

Snippet

Sponsor: Mesoblast, Inc. | Conditions: Grade B aGVHD, Grade C aGVHD | Phase 3 | Status: COMPLETED | Results posted: 2022-03-17